ストックスクリーナーアプリを入手
27.57
6.76%
-2.00
アフターアワーズ：
27.30
-0.27
-0.98%
前日終値:
$29.57
開ける：
$29.5
24時間の取引高:
411.26K
Relative Volume:
1.51
時価総額：
$1.32B
収益：
$20.00M
当期純損益:
$-107.28M
株価収益率:
-10.59
EPS:
-2.6031
ネットキャッシュフロー:
$-80.71M
1週間 パフォーマンス:
-10.05%
1か月 パフォーマンス:
-33.39%
6か月 パフォーマンス:
-30.27%
1年 パフォーマンス:
+10.86%
1日の値動き範囲:
$26.93
$29.75
1週間の範囲:
$26.93
$30.99
52週間の値動き範囲:
$23.75
$52.93
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Compare RAPP vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
27.57 | 1.32B | 20.00M | -107.28M | -80.71M | -2.6031 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-15 | 開始されました | UBS | Buy |
| 2026-10-15 | 開始されました | Wolfe Research | Outperform |
| 2026-10-06 | 開始されました | Guggenheim | Buy |
| 2026-07-28 | 開始されました | William Blair | Outperform |
| 2026-06-24 | 開始されました | Leerink Partners | Outperform |
| 2026-05-19 | 再開されました | Truist | Buy |
| 2026-04-10 | 開始されました | Raymond James | Strong Buy |
| 2026-02-02 | 開始されました | Wells Fargo | Overweight |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-09-16 | 開始されました | Truist | Buy |
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-08 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-07-02 | 開始されました | Jefferies | Buy |
| 2024-07-02 | 開始されました | Stifel | Buy |
| 2024-07-02 | 開始されました | TD Cowen | Buy |
すべてを表示
Rapport Therapeutics Inc (RAPP) 最新ニュース
Which Brain Pathways Is Rapport Therapeutics Trying to Tune? - Kalkine Media
Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com - Investing.com South Africa
Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock - Investing.com
Rapport Therapeutics CEO Abraham Ceesay sells $143,272 in stock By Investing.com - Investing.com South Africa
Form 4 Rapport Therapeutics Inc For: 10 October By Investing.com - Investing.com Canada
Form 144 RAPPORT THERAPEUTICS For: 6 October By Investing.com - Investing.com Canada
Guggenheim Initiates Rapport Therapeutics at Buy With $65 Price Target - marketscreener.com
Form 144 Rapport Therapeutics For: 1 October By Investing.com - Investing.com Nigeria
RAPP 10-Q FilingsRapport Therapeutics, Inc. SEC 10-Q - Stock Titan
Spyre Therapeutics (SYRE) Stock Price, News & Analysis - Stock Titan
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com India
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com Nigeria
Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com India
Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock - Investing.com
Form 4 Rapport Therapeutics Inc For: 24 September By Investing.com - Investing.com UK
Rapport Therapeutics CEO Ceesay sells $86,565 in company stock By Investing.com - Investing.com UK
RAPP Form 4 FilingsRapport Therapeutics, Inc. SEC Form 4 - Stock Titan
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo Finance
Why is Rapport Therapeutics stock sliding today? - Investing.com
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Raymond James reiterates Strong Buy on Rapport Therapeutics stock By Investing.com - Investing.com Nigeria
Raymond James reiterates Strong Buy on Rapport Therapeutics stock - Investing.com
Rapport Therapeutics (Nasdaq:RAPP)Stock Analysis - simplywall.st
Stifel reiterates Rapport Therapeutics stock rating on epilepsy drug outlook - Investing.com
Truist reiterates Buy on Rapport Therapeutics stock ahead of data - Investing.com
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Australia
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com India
Rapport Therapeutics CEO Abraham Ceesay sells $373,980 of common shares - Bitget
Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com Canada
Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com Nigeria
Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com India
Rapport Therapeutics at Cantor conference: pipeline breadth draws focus By Investing.com - Investing.com UK
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Nigeria
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com South Africa
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com South Africa
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock - Investing.com
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com Canada
Rapport Therapeutics Slides As Rally Loses Steam - TipRanks
Rapport Therapeutics (RAPP) Falls 4% to $44.24: Biotech Pullback Tests Trader PatienceWave Equality - siam.in
Rapport Therapeutics CEO Abraham Ceesay sells $374,497 in stock By Investing.com - Investing.com UK
Why (RAPP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RAPP 8-K FilingsRapport Therapeutics, Inc. SEC 8-K - Stock Titan
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - moomoo.com
Rapport Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
A biotech plans two September talks, one in New York and one online - Stock Titan
Rapport Therapeutics (RAPP) Slips 4% as Biotech Pullback Tests Key SupportRisk Reversal - dars.gov.et
Rapport Therapeutics (RAPP) Slips 4% as Biotech Pullback Tests Key SupportFast Moving Stocks - vinanet.vn
Rapport Therapeutics CEO Abraham Ceesay Sells 18,921 Shares Under Rule 10b5-1 Plan - Kalkine Media
Rapport (NASDAQ: RAPP) insider lines up stock sale after August plan trades - Stock Titan
Rapport Therapeutics Inc (RAPP) 財務データ
収益
当期純利益
現金流量
EPS
Rapport Therapeutics Inc (RAPP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Oct 07 '26 |
Sale |
30.66 |
1,147 |
35,167 |
452,245 |
| Abraham N. Ceesay | Officer |
Oct 06 '26 |
Proposed Sale |
31.15 |
39,470 |
1,229,490 |
0 |
| CHERYL GAULT | Officer |
Sep 30 '26 |
Proposed Sale |
33.02 |
10,000 |
330,200 |
0 |
| Gault Cheryl | Chief Operating Officer |
Sep 30 '26 |
Sale |
33.19 |
10,000 |
331,856 |
139,914 |
| Ceesay Abraham | Chief Executive Officer |
Sep 23 '26 |
Sale |
39.17 |
2,210 |
86,565 |
456,767 |
| Ceesay Abraham | Chief Executive Officer |
Sep 08 '26 |
Sale |
45.61 |
8,210 |
374,498 |
458,977 |
| KRISHNASWAMY YELESWARAM | Officer |
Aug 25 '26 |
Proposed Sale |
49.33 |
37,000 |
1,825,210 |
0 |
| Ceesay Abraham | Chief Executive Officer |
Aug 25 '26 |
Sale |
49.57 |
18,921 |
937,957 |
467,187 |
| Yeleswaram Krishnaswamy | Chief Development Officer |
Aug 25 '26 |
Sale |
50.64 |
37,000 |
1,873,605 |
195,862 |
| KRISHNASWAMY YELESWARAM | Officer |
Aug 24 '26 |
Proposed Sale |
48.24 |
11,472 |
553,409 |
0 |
3.29%
大文字化:
|
ボリューム (24 時間):